Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. - Innes AJ; Cook LB; Marks S; Bataillard E; Crossette-Thambiah C; Sivasubramaniam G; Apperley J; Milojkovic D (British journal of haematology, 2020)